Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that PD-L1 >= 5% status confers therapeutic sensitivity to Atezolizumab in patients with Bladder Urothelial Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression >= 5%.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2021-07-01 | Health Service Executive | Indication approved for reimbursement. |